308 related articles for article (PubMed ID: 12475827)
21. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the assessment of pleural abnormalities in cancer patients: a systematic review and a meta-analysis.
Treglia G; Sadeghi R; Annunziata S; Lococo F; Cafarotti S; Prior JO; Bertagna F; Ceriani L; Giovanella L
Lung Cancer; 2014 Jan; 83(1):1-7. PubMed ID: 24290256
[TBL] [Abstract][Full Text] [Related]
22. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
23. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography.
Toaff JS; Metser U; Gottfried M; Gur O; Deeb ME; Lievshitz G; Mercer D; Even-Sapir E
Invest Radiol; 2005 Apr; 40(4):204-9. PubMed ID: 15770138
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of PET-FDG imaging in differentiation of benign from malignant adrenal masses in lung cancer.
Gupta NC; Graeber GM; Tamim WJ; Rogers JS; Irisari L; Bishop HA
Clin Lung Cancer; 2001 Aug; 3(1):59-64. PubMed ID: 14656394
[TBL] [Abstract][Full Text] [Related]
25. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.
Orki A; Akin O; Tasci AE; Ciftci H; Urek S; Falay O; Kutlu CA
Thorac Cardiovasc Surg; 2009 Jun; 57(4):217-21. PubMed ID: 19670115
[TBL] [Abstract][Full Text] [Related]
26. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
27. Can PET/CT be used more effectively in pleural effusion evaluation?
Simsek FS; Yuksel D; Yaylali O; Aslan HS; Kılıçarslan E; Bir F; Arslan M; Can FE; Ugurlu E
Jpn J Radiol; 2021 Dec; 39(12):1186-1194. PubMed ID: 34165683
[TBL] [Abstract][Full Text] [Related]
28. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas.
Sperti C; Pasquali C; Chierichetti F; Liessi G; Ferlin G; Pedrazzoli S
Ann Surg; 2001 Nov; 234(5):675-80. PubMed ID: 11685032
[TBL] [Abstract][Full Text] [Related]
29. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
30. ¹⁸F-fluorodeoxyglucose PET/CT findings in pleural effusions of patients with known cancer. A cytopathological correlation.
Letovanec I; Allenbach G; Mihaescu A; Nicod Lalonde M; Schmidt S; Stupp R; Fitting JW; Boubaker A; Ris HB; Prior JO
Nuklearmedizin; 2012; 51(5):186-93. PubMed ID: 22584348
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
Flores RM; Akhurst T; Gonen M; Larson SM; Rusch VW
J Thorac Cardiovasc Surg; 2003 Jul; 126(1):11-6. PubMed ID: 12878934
[TBL] [Abstract][Full Text] [Related]
32. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG PET imaging in assessing exudative pleural effusions.
Duysinx BC; Larock MP; Nguyen D; Corhay JL; Bury T; Hustinx R; Louis R
Nucl Med Commun; 2006 Dec; 27(12):971-6. PubMed ID: 17088683
[TBL] [Abstract][Full Text] [Related]
34. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.
Porcel JM; Hernández P; Martínez-Alonso M; Bielsa S; Salud A
Chest; 2015 Feb; 147(2):502-512. PubMed ID: 25188411
[TBL] [Abstract][Full Text] [Related]
35. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
36. Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.
Huang YC; Tu DG; Wu JD; Lee MY
Spine (Phila Pa 1976); 2009 Oct; 34(21):E780-3. PubMed ID: 19934799
[TBL] [Abstract][Full Text] [Related]
37. Differential diagnosis between benign and malignant pleural effusion with dual-energy spectral CT.
Zhang X; Duan H; Yu Y; Ma C; Ren Z; Lei Y; He T; Zhang M
PLoS One; 2018; 13(4):e0193714. PubMed ID: 29641601
[TBL] [Abstract][Full Text] [Related]
38. The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.
Kahn D; Menda Y; Kernstine K; Bushnell D; McLaughlin K; Miller S; Berbaum K
Chest; 2004 Feb; 125(2):494-501. PubMed ID: 14769730
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management.
Dewan NA; Gupta NC; Redepenning LS; Phalen JJ; Frick MP
Chest; 1993 Oct; 104(4):997-1002. PubMed ID: 8404239
[TBL] [Abstract][Full Text] [Related]
40. Indeterminate pleural metastasis on contrast-enhanced chest CT in non-small cell lung cancer: improved differential diagnosis with (18)F-FDG PET/CT.
Jung MY; Chong A; Seon HJ; Choi S; Kim YH; Shin SS; Kim JW; Bom HS
Ann Nucl Med; 2012 May; 26(4):327-36. PubMed ID: 22350956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
